Ad copy

After 12 years as an electrophysiology cardiologist at one of the top cardiac centers in America, I discovered why a small fishing village in Okinawa has nearly zero strokes while Americans on $562 a month blood thinners are bleeding from paper cuts and stroking anyway, by the hundreds of thousands every year. Japanese researchers studied them for 16 years. 29,079 people followed. Found the answer. Then American medicine made sure the research never made it into our training. Because the stroke isn't a problem they want to prevent. It's a 13 billion dollar a year industry called Eliquis. But I quit that system. And I'm done being silent. My name is Dr. James Caldwell. Electrophysiology cardiologist. 12 years prescribing Eliquis and Xarelto at one of the top cardiac centers in the country. I got into medicine to save people from strokes. Instead, I spent 12 years handing them a different way to die. That's what blood thinners do. They don't fix what's causing the clot. They just stop your blood from clotting at all. Which means every paper cut, every bruise, every dental cleaning, every fall in the bathroom becomes a potential bleed-out. Every week, the same pattern. A patient walks into my office. AFib diagnosis. 65, 68, 72 years old. Still strong. Still active. They trust me to protect them from a stroke. So I prescribe what I was trained to prescribe. Eliquis. Xarelto. Pradaxa. Sometimes warfarin if they can't afford the new ones. Drugs that stop your blood from clotting. Including the clots your body actually needs. Their skin starts bruising from grocery bags. They can't take ibuprofen for their back anymore. A dental cleaning becomes a two-week coordination project. They cut their arm on a manila envelope and it bleeds for 40 minutes. But the stroke risk drops. For a while. Then they fall in the bathroom. Or they cut themselves shaving. Or they have a brain bleed in their sleep. And we find them in the morning. So we try a different cocktail. Lower the dose. Add metoprolol. Add lisinopril. More pills. More side effects. And you know what happens? A lot of them stroke anyway. Not because the blood thinner failed. Because the blood thinner was never addressing the actual mechanism. It was just suppressing a symptom while the underlying problem, the enzyme their liver stopped making, kept getting worse. I watched this for 12 years. Prescribed the protocols. Watched my patients bruise, bleed, fall, stroke. Watched them die from brain bleeds caused by the very drug supposed to prevent the brain bleed. Then I'd go to cardiology conferences where we'd celebrate stroke reduction rates. "Eliquis reduces stroke risk by 21% over warfarin." They cheered. Like 21% was a victory. That means most of the strokes still happen. The patients who don't stroke spend their last decade bruised. Terrified. Broke from copays. Unable to ride a motorcycle. Unable to prune the roses. Unable to cut their own steak without their wife flinching. And Bristol Myers Squibb made 13 billion dollars last year from Eliquis alone. 13 billion dollars. From one drug. One AFib patient on Eliquis. $562 a month. $6,744 a year. For life. Until the stroke or the brain bleed comes anyway. A patient whose body actually fixes the underlying problem? Worth nothing. Here's what they don't tell you in residency. The stroke isn't too hard to prevent. It's too profitable to prevent properly. The doctors aren't the problem. We're working with what we were taught. But medical schools don't teach fibrinolytic restoration. They don't teach what the Japanese figured out in 1987. They teach pharmaceutical protocols written by the same companies making the pharmaceuticals. I practiced medicine to save people's lives. Not to bruise them, bleed them, and bill them $562 a month while they wait for the bleed that ends it. So I started looking for answers outside the system. Late nights in my office. Scrolling through international cardiac research. Looking for any population with a low stroke rate. Anything that could explain why my patients on the best drugs in the world were still dying. That's when I found it. A study from Tsumura University in Japan. Published in 1987 by a researcher named Hiroyuki Sumi. Stroke rate in coastal Japan: one fifth of America's. In some villages, almost nonexistent. I thought it had to be a data error. How could a population eating high-sodium fermented food, with no statins, no Eliquis, no Xarelto, have stroke rates we couldn't match with $6,744 a year per patient? But the study was solid. 29,079 people followed for 16 years. 25% fewer cardiovascular deaths in the group consuming a specific food daily. So I dug deeper. The Japanese don't smoke at lower rates. They drink more sake than Americans drink wine. They eat plenty of salt. There had to be something else. I found a second paper. This one from a researcher at the University of Chicago who tried to bring Sumi's work to the United States in the late 1980s. The funding never came. The American Heart Association didn't pick it up. No pharmaceutical company wanted to fund replication studies on a food they couldn't patent. The paper sat in a Japanese journal almost no American doctor reads. For 39 years. Here's what those papers found. The Japanese consume something most Americans don't. Something Japanese farmers have eaten every morning for more than a thousand years. Something they ferment in straw the way their grandmothers did. The researchers found a specific enzyme in their blood at concentrations 8 times higher than the average American over 50. That enzyme breaks down small clots inside the arteries before they grow into the big one. Not by thinning the blood. By dissolving the fibrin meshwork the clot is built from. The body makes it on its own. Until about age 50. After 50, production drops. By 65, most of it is gone. The clots that used to dissolve now stay. They build. One breaks loose. And that's what we call a stroke. The Japanese keep making the enzyme. Through what they eat. Think of it this way. Your blood thinner is like cutting off the water to a leaking pipe. Sure, the leak stops. But now nothing in the house works. You can't shower. You can't drink. You can't wash dishes. Every tap is broken. What the Japanese eat is like fixing the pipe. Their bodies stay normal. Their blood clots when they cut themselves. They don't bruise from grocery bags. They don't bleed from rose thorns for 40 minutes. And the strokes that should be happening, aren't. Sumi concluded that if older Americans consumed this enzyme at Japanese levels, age-related stroke rates could drop substantially. That research has been public since 1987. It has never been incorporated into American cardiology training. Not once. Not on any pharma-sponsored slide deck. Bristol Myers Squibb couldn't let this get traction. A meaningful drop in stroke risk through a fermented soybean would cost them billions in Eliquis sales per year. So what are the Japanese eating? Natto. The fermented soybean their grandmothers made in straw bundles. Bitter taste. Stringy texture. Most Americans gag the first time they try it. But not the natto you find in a health food store. The Japanese use a specific bacterial strain called Bacillus subtilis natto. Fermented in a specific way that produces the enzyme at clinical concentrations. The Japanese isolated this strain in the 1980s. They named it NSK-SD. Outside of NSK-SD, the enzyme is barely there. I decided to try it with my patients. Ordered nattokinase supplements online. 9 different American brands. All claiming to be high-potency and clinically dosed. I gave them to my AFib patients alongside their existing Eliquis protocol. 3 months later, I checked their lab work. Fibrinogen barely moved. D-dimer barely moved. Blood pressure barely moved. None of those brands were delivering the dose. Or the strain. Or both. I felt like an idiot. American medicine had betrayed me. Now the supplement industry was betraying me too. I quit. Walked away from 12 years at the top cardiac center in my region. I was done participating in a system where the drug bleeds you, the supplements lie to you, and the patient pays $562 a month for the privilege. Then I got a phone call that changed everything. "Dr. Caldwell, do you remember me? This is Tom. From two years ago. AFib. CHA2DS2-VASc score of 3. You started me on Eliquis." Of course I remembered Tom. 65 at the time. Retired electrical contractor in Tennessee. We'd put him on Eliquis 5mg twice daily after a paroxysmal AFib episode. His copay was $562. He'd hated the bruising. Hated the bleed times. Hated paying. "I want to thank you. For something you didn't even do." I didn't understand. The last time I saw Tom, he was on Eliquis bruising up his forearms. Wife scared every time he reached for a steak knife. "Doc, after you moved practices, I found a new EP. I told him I couldn't do this for another decade. He said most cardiologists wouldn't work with me on this. But he was open. He'd seen the Sumi research. We tapered the Eliquis slowly. I added a real nattokinase. The right one. He tracked my fibrinogen. My D-dimer. My CT angiogram. Doc, I've been off Eliquis for 11 months. Fibrinogen in the 280s. BP 122/74. No AFib episodes since the taper. I went motorcycle riding again. I pruned the roses. My wife stopped flinching when I reached for a knife." I told him I'd visit. The entire drive to Tom's house, my mind was racing. A 67-year-old AFib patient. Off Eliquis for 11 months. Fibrinogen in the 280s. No incidents. This doesn't happen. Not with the standard of care we're trained to provide. When I walked into his garage, I didn't recognize the man. The Tom I remembered was 195 pounds. Gray. Bruised. Scared. The man working on a 1998 Harley in front of me was 180 pounds. Color in his face. Laughing with his grandson holding a wrench. His wife came out with iced tea. "The nattokinase. He takes it religiously. 3 capsules twice a day. The new doctor watches his labs every 90 days." I asked to see the bottle. She brought it out. First thing I noticed: "JNKA-certified NSK-SD" stamped on the front. The original Japanese strain. The one in every clinical study since 1987. Then the back label. "10,800 FU per serving. K2 MK-7 included for vascular calcium clearance. Per-batch lab report. Scan QR code." This was it. Someone had finally built what the Sumi research described. Clinical dose. Original strain. Per-batch verification you could scan with your phone. I asked if I could take a bottle. They gave me three. That night, I called the company. Corvael. I started interrogating them like I was reviewing a clinical trial. "Where is the strain sourced?" "JNKA-licensed Japanese supplier. NSK-SD only. Documentation on file for every batch." "Can you prove the 10,800 FU per cap?" They sent the assay reports. Per-batch testing. Third-party laboratory in the United States. ISO 17025 certified. "Heavy metals. Microbials. K2 source." Within an hour I had the full Certificate of Analysis. Heavy metals undetectable. Microbials within spec. K2 MK-7 at 180 mcg from natto fermentation. Not synthetic. I still didn't trust it. So I sent the bottle Tom gave me to the same lab my cardiac center used. Results came back. NSK-SD strain confirmed by PCR. 10,400 FU per cap. Within 4% of label claim. 178 mcg K2 MK-7. Zero heavy metals. Zero microbials. Zero fillers. This was real. This was what Sumi documented. This was what no American company had bothered to do correctly until now. I reached out to 14 of my former AFib patients. Most still on Eliquis. Some on warfarin. A few who had quit cold turkey against medical advice. "I found something. I can't promise anything. But I need you to bring this to your cardiologist and have a real conversation with them." 12 agreed. 2 had already passed since I'd last seen them. One stroke. One brain bleed. These weren't mild cases. 68-year-old on Eliquis 5mg twice daily, fibrinogen at 408. 72-year-old on warfarin, INR all over the place, bruising weekly. 66-year-old on Pradaxa with kidney function declining. 70-year-old who had stopped his Eliquis on his own 3 months earlier. Terrified. I checked in every 90 days. After 6 months the pattern was clear. The patients whose new doctors actually worked with them. Monitored their labs. Adjusted slowly. They were the ones whose lives came back. Fibrinogen dropping. Bruising stopped. Energy returning. 2 of them got off Eliquis entirely under their cardiologist's supervision. Several reduced their dose. One stayed on full dose plus Corvael and just stopped bruising. The K2 made the difference for him. Tom is still off. 23 months now. Gerald, 70, persistent AFib. Dose reduced from 5mg twice daily to 2.5mg twice daily under cardiology supervision. Fibrinogen from 380 to 290. Bruising stopped. Copay cut in half. Linda, 66, on Pradaxa. Added Corvael with her doctor's approval. Fibrinogen normalized. Kidney function stabilized. She's still on the drug but no longer worried about it. The side effects they reported from the nattokinase. "Nothing. No nausea. No headaches. No anything." "My bruises went away within 6 weeks. That alone is worth it." "My wife isn't scared anymore." "My grandson's birthday was the first one in 5 years I didn't wear long sleeves." Before recommending Corvael to anyone else, I tested 7 other American nattokinase brands. Because I'm a cardiologist. I don't trust labels. The American supplement industry has been lying for 30 years. ProBlue Nattokinase. Claimed 10,000 FU. Lab tested at 2,400 FU. Less than a quarter of the label. Heart Defender NK. Claimed JNKA-certified. Was not. Letter from JNKA confirmed no licensing agreement. NutraVascular Nattokinase. Claimed NSK-SD strain. Strain testing returned a completely different Bacillus species. 3 others. Under-dosed by 50% or more. One had fillers and binders making up half the capsule weight. The last one was rancid. The natto extract had oxidized. The enzyme was already denatured before the bottle ever shipped. Taking it would have done literally nothing. The only one that matched what the Japanese consume. The only one with the strain, the dose, the K2, the per-batch verification, the clean COA. Was Corvael. JNKA-certified NSK-SD. 10,000 FU per cap. K2 MK-7 included. Per-batch QR-coded COA you can scan with your phone before you swallow the first capsule. Made in an American GMP-certified facility. Zero contamination. Every former patient who calls me now gets the same information. I told my old colleagues. They told me I'd lost my mind. "If something like that worked, we'd be using it." That's exactly the problem. I spent 12 years in that system. I know how it works. Anticoagulant prescriptions in America generate over 20 billion dollars per year. Eliquis alone is 13 billion. Xarelto is 8 billion. Bristol Myers Squibb isn't trying to find a path that lets patients restore their own fibrinolytic capacity. They're trying to sell more Eliquis. Until the patient strokes or bleeds out or runs out of Medicare donut hole money. Whichever comes first. A 68-year-old AFib patient on Eliquis for the next 12 years is worth $80,000 to Bristol Myers Squibb over his remaining life. A patient who works with his cardiologist to restore his own clot-dissolving enzyme through a $40 bottle is worth nothing. The doctors aren't evil. They're doing exactly what they were trained to do. But cardiology residencies don't teach fibrinolytic restoration. They don't teach the Sumi research. They don't teach what Japanese farmers have known for a thousand years. They teach Eliquis, warfarin, ablation, Watchman. Because that's what generates billable codes. If you have AFib, or someone you love does, listen carefully. Every day, your liver is supposed to be producing a clot-dissolving enzyme. Right now. In your body. If you're over 65, it has likely dropped 60% or more. In a healthy young body, that enzyme dissolves small clots inside your arteries before they grow into the big one. Without that enzyme, the small clots stay. They build. One breaks loose. That's the stroke. That's why people on Eliquis still stroke. The drug doesn't restore the enzyme. It just stops blood from clotting at all. Which is why you also bruise from a doorframe. The Japanese maintain the enzyme. Through what they eat every morning. Their stroke rate is one fifth of ours. Their bleeding rate from minor cuts is normal. That's why their men live to 87 with no Eliquis prescription, while ours die at 68 despite $6,744 a year in copays. Not because of genetics. Because of what their liver is still doing. Because of what they consume daily to keep doing it. Sumi proved it. Chen replicated it in 2022 with 1,062 patients. 36% reduction in carotid plaque over 12 months on clinically dosed nattokinase. Bristol Myers Squibb has not funded a single American replication study. There's no money in it for them. I'm not telling you to stop your blood thinner. I'm not a fool. AFib without anticoagulation is a stroke waiting to happen for some patients. But I am telling you this. Eliquis without fibrinolytic support is like turning off the water in a leaking house. Sure, the leak stops. But your whole life shuts down with it. You need to bring something to your cardiologist that addresses the actual mechanism your body has lost. Then let your cardiologist decide what to adjust, when to monitor, what to taper, what to keep. Don't buy a random nattokinase off Amazon. I tested them. Most are worthless. Wrong strain. Under-dosed. Or already oxidized in the bottle. The only one I personally lab-verified. The only one that matches the Sumi research and helped Tom get off Eliquis under his cardiologist's supervision. Is Corvael. In case you want to bring it to your doctor, here's the link: https://corvael.com It costs more than the junk you see in the supplement aisle. I believe that's because sourcing JNKA-certified NSK-SD strain from Japan, dosing it to clinical levels, including K2 MK-7, and running per-batch third-party assays costs more than the shortcuts everyone else uses. P.S. If you're currently on Eliquis, Xarelto, Pradaxa, or warfarin, your fibrinolytic enzyme production is already low. That's why you needed the prescription in the first place. The prescription doesn't restore the enzyme. It just stops the bleeding consequence. Bring the Corvael lab report to your cardiologist at your next appointment. Watch his face while he reads it. That's when you'll know whether he's your doctor or just your prescriber. P.P.S. I don't work for Corvael. I don't get paid to recommend them. I quit a $400,000 a year EP cardiology position because I was tired of watching patients bruise, bleed, and stroke anyway on a drug that doesn't address the actual mechanism. After 12 years at one of the top cardiac centers in America, I finally found a bottle that delivers what the Japanese have been eating for a thousand years. And I'm not staying quiet while AFib patients pay $562 a month to bleed from paper cuts for a drug that was never going to restore what their bodies actually lost.